Mirabegron - Astellas Pharma

Drug Profile

Mirabegron - Astellas Pharma

Alternative Names: Betanis; Betmiga; Myrbetriq; YM-178

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Johns Hopkins University
  • Class Acetamides; Ethanolamines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • Phase III Interstitial cystitis
  • Phase I/II Erectile dysfunction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 14 Feb 2018 Astellas Pharma completes a phase II trial for Overactive bladder in Japan (PO) (UMIN000014150)
  • 11 Dec 2017 Phase-III clinical trials in Overactive bladder (In adolescents, In children) in Japan (PO) (Astellas Pharma pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Overactive bladder(In adolescents, In children) in Germany (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top